安旭生物(688075) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 115,296,526.87, a decrease of 10.9% compared to CNY 129,406,701.97 in the same period last year[4]. - Net profit attributable to shareholders decreased by 51.52% to CNY 34,029,618.77 from CNY 70,190,798.47 year-on-year[4]. - The net profit after deducting non-recurring gains and losses increased by 15.95% to CNY 22,760,297.27 compared to CNY 19,629,646.53 in the previous year[4]. - Net profit for Q1 2025 was CNY 34,227,418.43, down 51.3% from CNY 70,334,720.12 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, compared to CNY 0.55 in Q1 2024[20]. - The company reported a decrease in comprehensive income to CNY 32,331,616.02 in Q1 2025 from CNY 70,370,450.36 in Q1 2024[20]. Cash Flow - The net cash flow from operating activities was negative at CNY -11,098,782.01, compared to a positive CNY 1,008,618.28 in the same period last year[4]. - Net cash flow from operating activities was -$11.1 million, a decrease from $1.0 million in the previous period[23]. - Cash paid for operating activities totaled $138.6 million, compared to $166.1 million last year[23]. - Cash received from sales in Q1 2025 was CNY 103,961,347.43, a decrease from CNY 110,735,727.41 in Q1 2024[22]. - The company reported a net increase in cash and cash equivalents of -$31.8 million, compared to an increase of $321.7 million last year[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,844,995,156.61, reflecting a 1.31% increase from CNY 5,769,310,895.27 at the end of the previous year[5]. - Current assets totaled RMB 4,847,904,481.23, compared to RMB 4,769,982,927.28 at the end of 2024, reflecting a growth of approximately 1.6%[13]. - Total liabilities reached RMB 612,876,253.81, compared to RMB 569,523,608.49 at the end of 2024, marking an increase of about 7.6%[14]. - The company's non-current assets totaled RMB 997,090,675.38, slightly down from RMB 999,327,967.99[14]. - The company's total equity attributable to shareholders was CNY 5,235,733,004.95, reflecting a slight increase from CNY 5,203,599,188.59[15]. Research and Development - Research and development expenses totaled CNY 25,058,704.57, representing an increase of 26.3% from CNY 19,840,217.39 year-on-year[4]. - Research and development expenses rose to CNY 25,058,704.57 in Q1 2025, an increase of 26.5% from CNY 19,840,217.39 in Q1 2024[19]. Non-Recurring Items - The company reported non-recurring gains of CNY 11,269,321.50 after tax, primarily due to government subsidies and other non-operating income[7]. - Other income decreased significantly to CNY 1,725,120.33 in Q1 2025 from CNY 13,159,386.79 in Q1 2024[19]. Inventory and Receivables - The company reported a significant increase in inventory, which stood at RMB 143,539,795.97, compared to RMB 147,167,029.08 previously[13]. - Accounts receivable increased to RMB 283,512,930.50, up from RMB 203,690,596.91, representing a significant rise of approximately 39.2%[13]. Other Information - The total number of ordinary shareholders at the end of the reporting period was 5,935[9]. - The company has not disclosed any new product launches or technological advancements during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current financial period[12].